Fig. 11

CB65 induces proliferation of hSSCs. CB65 increases the percentage of hSSCs in A. G2/M phases on day 10 and (B) G0/G1 phases on day 12 by PI labeling. (C) CB65 at submaximal dose increases the percentage of hSSCs in G2/M and G0/G1 phases on day 10 and 12, respectively, compared to medium, medium vehicle (%0.001 DMSO), AM630 and CB65 + AM630 applied groups. *p < 0.0001